(News Bulletin 247) – Novo Nordisk today announced the results of a phase 3 trial showing that, compared to placebo, semaglutide 2.4 mg given once a week led to a significant reduction in symptoms related to heart failure and caused greater weight loss in adults with heart failure with preserved ejection fraction (HFpEF) and obesity.
‘As clinicians, we have limited treatment options to offer our patients living with HFpEF and obesity. Yet it is a disease that seriously affects the daily experience of patients, due to debilitating symptoms and functional limitations,’ said Dr Mikhail Kosiborod, the study’s principal investigator and cardiologist at Saint Luke’s Mid America Heart Institute, in Kansas City (USA).
‘Today’s news signals a possible fundamental paradigm shift in how cardiologists approach HFpEF in people with obesity. It is gratifying to be able to share important evidence that has the potential to change the future clinical management of this vulnerable patient population,” he added.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
